FDA Brief

Warning letters Food

FDA warning letter to

Fibromyalgia Treatment Group - FTG, LLC

High riskIssued Aug 26, 2021Posted Sep 21, 2021Division of Human and Animal Food Operations West VI

FDA warned Fibromyalgia Treatment Group that its Fibrolief, Nerve Renew and other supplements are unapproved new drugs sold with disease-treatment claims.

What happened

FDA reviewed four company websites (fibromyalgiatreatmentgroup.com, fibrolief.com, neuropathytreatmentgroup.com and nerverenew.com) plus a Facebook page in August 2021 and found the firm takes orders there for Fibrolief Support Formula, Nerve Renew, Neuro Boost Optimizer and Immune Support. The pages carried claims that these products treat fibromyalgia, nerve pain, depression, migraines and infections, backed by customer testimonials. One page also said "Our manufacturing facility is FDA approved," which FDA says is false because it does not approve dietary supplement plants. There was no inspection.

What FDA found

  1. Website claims that the supplements cure, treat or prevent fibromyalgia, nerve pain, depression and infections make them drugs under the law.

    section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]
  2. Because the products are not generally recognized as safe and effective for those uses, they are "new drugs" that cannot be sold without FDA approval, which the company does not have.

    sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. § 321(p), § 331(d), § 355(a)]
  3. The products are misbranded because they carry no adequate directions for use, and directions a layperson could follow safely cannot be written for diseases that need a licensed practitioner's care.

    section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. Shipping these misbranded drugs across state lines is itself a violation.

    section 301(a) of the Act [21 U.S.C. § 331(a)]
  5. The claim that the manufacturing facility is "FDA approved" is false or misleading, and would misbrand the product as a food even if it were not a drug.

    section 403(a)(1) of the Act [21 U.S.C. § 343(a)(1)]

What FDA wants

FDA asks the company to reply in writing within 15 working days describing the specific steps taken to correct each violation, how recurrence will be prevented, and with copies of supporting documents. If the fixes cannot be finished in that time, the company must say why and give the date it will finish.

Who should pay attention

  • dietary supplement brands that make disease-treatment claims on their websites or social media
  • companies running landing pages and affiliate marketing for health products
  • supplement marketers who describe their manufacturing plant as "FDA approved"

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk